- In December 2023, Roche has acquired select parts of LumiraDx’s innovative Point of Care technology, enhancing its diagnostics portfolio. This acquisition enables faster, more affordable testing across multiple disease areas. The integration of LumiraDx’s platform will improve patient access to timely, accurate diagnostic results in decentralized healthcare settings globally
- In January 2025, Danaher Corporation has formed an investment partnership with Innovaccer Inc., a healthcare AI company. This collaboration aims to accelerate the adoption of precision diagnostics and value-based care by providing healthcare providers with unified patient data and advanced analytics, improving patient outcomes through personalized, timely interventions
- In October 2024, bioMérieux has called for multi-sector collaboration to advance the global agenda on antimicrobial resistance (AMR). The company emphasizes the urgent need for combined efforts from healthcare, government, and industry to address AMR, promoting innovative diagnostic solutions and responsible antimicrobial usage to combat this growing global health threat
- In March 2024, Bio-Rad Launched XP-Design Assay Salmonella Serotyping Solution for Rapid and Accurate Food Safety Testing. The XP-Design Assay Salmonella Serotyping Solution provided a flexible approach to identify Salmonella serotypes after initial screening. The ready-to-use solution contains oligonucleotides (primers and probes) that are specific to the target serotype ensuring high specificity and reduces the risk of cross-reaction, delivering reliable results
